Background The only two preparations of botulinum toxin A for which there are published
evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox®) and …

Introduction Spasticity has been considered to be a main contributor to both the impairment
of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb …

At the University Hospital of Pellenberg (Belgium), more than 1000 patients have been
treated with Botulinum toxin type A (BTX-A) over the last decade. Ten percent of these …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

The treatment of children with cerebral palsy with Botulinum Toxin is considered safe and
effective, but is only approved for children older than two years of age. The effect of BoNT-A …

BACKGROUND: Botulinum toxin type A (BoNT-A) has been used in many indications and is
licensed for the treatment of spasticity in children older than 2years. However, there are few …

Background: Cerebral palsy (CP) is one of the most common causes of activity limitation in
children. Botulinum toxin (BoNT-A) is relatively recent addition to the available medical …

The current modalities in managing spastic children have some limitations; thus, alternative
therapeutic agents are in need. The purpose of this study is to investigate whether …

Background: Botulinum neurotoxins type A (BoNT-As) are used in pediatric lower limb
spasticity, which affects more than 2.5 million children worldwide. Botulinum neurotoxins …

Objectives: To determine whether switching from onabotulinumtoxin-A to abobotulinumtoxin-
A in children with cerebral palsy is safe and whether therapeutic efficacy is maintained …